Clinical Trial Update: Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension [Phase 3]

View source ↗

Summary

A long-term safety study of aliskiren, alone or with hydrochlorothiazide, in essential hypertension has completed Phase 3 testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Tekturna (aliskiren)
• Tekturna HCT (aliskiren/hydrochlorothiazide)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED